{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:44:13Z","timestamp":1792107853314,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijrobp.2022.10.025","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:16:26Z","timestamp":1666574186000},"page":"886-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial"],"prefix":"10.1016","volume":"115","author":[{"given":"Fabio","family":"Arcidiacono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Anselmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zannori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mancioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Loreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Italiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.10.025_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0002","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.2011.39.5269","article-title":"Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0004","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: A prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0006","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.lungcan.2013.06.011","article-title":"Effectivenes of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer","volume":"82","author":"Sigel","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0007","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.prro.2015.02.012","article-title":"Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline","volume":"5","author":"Rodrigues","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0009","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2004.04.013","article-title":"Improved local control with higher doses of radiation in large-volume stage III non\u2013small-cell lung cancer","volume":"60","author":"Rengan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0012","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non\u2013small-cell lung cancer: A phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0013","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0014","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis","volume":"30","author":"Mauguen","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0015","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1016\/S1470-2045(15)70121-X","article-title":"Radiotherapy dose and fractionation for stage III NSCLC","volume":"16","author":"Jos\u00e9 Belderbos","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200645","article-title":"Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients","volume":"93","author":"Arcidiacono","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0017","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0018","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0019","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2015.07.031","article-title":"The effect of travel distance on radiotherapy utilization in NSW and ACT","volume":"117","author":"Gabriel","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.21037\/tlcr-2020-nsclc-04","article-title":"Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer","volume":"10","author":"Alcibar","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0021","first-page":"886","article-title":"Simultaneous integrated protection. A new concept for high-precision radiation therapy","volume":"190","author":"Thomas","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0022","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: Phase 1 dose escalation trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0023","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0024","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1 update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2022.10.025_bib0025","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0026","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/1759-7714.13451","article-title":"Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review","volume":"11","author":"Zehentmayr","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0027","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2019.08.034","article-title":"Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC)","volume":"105","author":"Raben","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0028","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.22.00204","article-title":"Durvalumab induces sustained survival benefit after concurrent chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Pujol","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0029","first-page":"953","article-title":"Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: Potential role for stereotactic body radiotherapy","volume":"30","author":"Nguyen","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: A systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0031","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ijrobp.2020.03.038","article-title":"Survival and toxicity of hypofractionated intensity modulated radiation therapy in 4 Gy fractions for unresectable stage III non-small cell lung cancer","volume":"107","author":"Kong","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0032","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-019-01566-z","article-title":"Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"25","author":"Ito","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0033","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtho.2018.06.007","article-title":"Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy","volume":"13","author":"Shiue","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0034","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtho.2017.12.011","article-title":"A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"13","author":"Nyg\u00e5rd","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0035","first-page":"59","article-title":"Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities","volume":"5","author":"Karam","year":"2014","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0036","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0037","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: Final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COC.0000000000000892","article-title":"Stereotactic body radiotherapy and systemic dose chemotherapy for locally advanced lung cancer: Single arm phase 2 study","volume":"45","author":"Kubicek","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0039","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2007.06.034","article-title":"Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer","volume":"70","author":"Werner-Wasik","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2005.07.967","article-title":"Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume","volume":"64","author":"Basaki","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0041","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3390\/cancers12103035","article-title":"Association of planning target volume with patient outcome in inoperable stage III NSCLC treated with chemoradiotherapy: A comprehensive single-center analysis","volume":"12","author":"Karin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0042","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0043","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.ijrobp.2022.10.025_bib0044","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/1759-7714.12764","article-title":"Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the \u201cno fly\u201d zone","volume":"9","author":"Ahmed","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0046","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMc1203770","article-title":"Central-airway necrosis after stereotactic body-radiation therapy","volume":"366","author":"Corradetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0047","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: How to fly in a \u201cno fly zone\u201d","volume":"88","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0048","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0049","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","article-title":"Tumor control and toxicity after SBRT for ultracentral, central, and paramediastinal lung tumors","volume":"9","author":"Nguyen","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.10.025_bib0051","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622034599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622034599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:03:48Z","timestamp":1759745028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622034599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0360301622034599"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.10.025","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}